ArticleFrontiers in biology2015
New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease.
Article in Frontiers in biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Deletion ofFrontiers in cellular neuroscience · 2026Article
- Deletion ofbioRxiv : the preprint server for biology · 2025Article
- Sensitive dLight3 for imaging broad-spectrum dopamine events across brain regions.Research square · 2025Article
- Generation and validation of a D1 dopamine receptor Flpo knock-in mouse.Journal of neuroscience methods · 2025Article
- An ultra low frequency spike timing dependent plasticity based approach for reducing alcohol drinking.Scientific reports · 2024Article
- 2-(Fluoromethoxy)-4'-(Journal of medicinal chemistry · 2022Article
- Ligand recognition and biased agonism of the D1 dopamine receptor.Nature communications · 2022Article
- The organic cation transporter 2 regulates dopamine D1 receptor signaling at the Golgi apparatus.eLife · 2022Article
- Medial prefrontal cortex and the temporal control of action.International review of neurobiology · 2021Review
- Deferred Administration of Afobazole Induces Sigma1R-Dependent Restoration of Striatal Dopamine Content in a Mouse Model of Parkinson's Disease.International journal of molecular sciences · 2020Article
- PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial.Therapeutic advances in neurological disorders · 2020Article
- Designing Functionally Selective Noncatechol Dopamine DACS chemical neuroscience · 2019Article
- Dopamine and addiction: what have we learned from 40 years of research.Journal of neural transmission (Vienna, Austria : 1996) · 2019Review
- Projection targets of medial frontal D1DR-expressing neurons.Neuroscience letters · 2017Article
- Infusion of D1 Dopamine Receptor Agonist into Medial Frontal Cortex Disrupts Neural Correlates of Interval Timing.Frontiers in behavioral neuroscience · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The neurotransmitter dopamine acts via two major classes of receptors, D1-type and D2-type. D1 receptors are highly expressed in the striatum and can also be found in the cerebral cortex. Here we review the role of D1 dopamine signaling in two major domains: L-DOPA-induced dyskinesias in Parkinson's disease and cognition in neuropsychiatric disorders. While there are many drugs targeting D2-type receptors, there are no drugs that specifically target D1 receptors. It has been difficult to use selective D1-receptor agonists for clinical applications due to issues with bioavailability, binding affinity, pharmacological kinetics, and side effects. We propose potential therapies that selectively modulate D1 dopamine signaling by targeting second messengers downstream of D1 receptors, allosteric modulators, or by making targeted modifications to D1-receptor machinery. The development of therapies specific to D1-receptor signaling could be a new frontier in the treatment of neurological and psychiatric disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.